BioXcel Therapeutics Inc.

34.57-0.5000-1.43%Vol 398.03K1Y Perf 44.56%
Apr 13th, 2021 15:41 DELAYED
BID34.53 ASK34.61
Open35.00 Previous Close35.07
Pre-Market- After-Market-
 - -%  - -
Target Price
108.10 
Analyst Rating
Strong Buy 1.00
Potential %
213.61 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap849.49M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
26.05 
Earnings Date
11th May 2021

Today's Price Range

33.7535.46

52W Range

21.5671.50

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.37%
1 Month
-25.37%
3 Months
-31.05%
6 Months
-35.62%
1 Year
44.56%
3 Years
279.96%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BTAI34.57-0.5000-1.43
AAPL134.423.18002.42
GOOG2 267.6112.82000.57
MSFT258.322.41000.94
XOM55.690.19000.34
WFC39.80-0.9700-2.38
JNJ159.42-2.2200-1.37
FB310.27-1.2700-0.41
GE13.48-0.1100-0.81
JPM154.25-1.7000-1.09
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.87-0.870.00
Q03 2020-0.80-1.07-33.75
Q02 2020-0.74-1.06-43.24
Q01 2020-0.55-0.79-43.64
Q04 2019-0.67-0.4532.84
Q03 2019-0.59-0.573.39
Q02 2019-0.52-0.54-3.85
Q01 2019-0.48-0.464.17
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.89-18.67Negative
6/2021 QR-0.97-19.75Negative
12/2021 FY-4.29-10.57Negative
12/2022 FY-2.66-45.36Negative
Next Report Date11th May 2021
Estimated EPS Next Report-0.89
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume398.03K
Shares Outstanding24.57M
Trades Count4.97K
Dollar Volume28.44M
Avg. Volume581.63K
Avg. Weekly Volume357.11K
Avg. Monthly Volume587.23K
Avg. Quarterly Volume547.57K

BioXcel Therapeutics Inc. (NASDAQ: BTAI) stock closed at 35.07 per share at the end of the most recent trading day (a -2.23% change compared to the prior day closing price) with a volume of 281.73K shares and market capitalization of 849.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. BioXcel Therapeutics Inc. CEO is Vimal Mehta.

The one-year performance of BioXcel Therapeutics Inc. stock is 44.56%, while year-to-date (YTD) performance is -24.09%. BTAI stock has a five-year performance of %. Its 52-week range is between 21.56 and 71.5, which gives BTAI stock a 52-week price range ratio of 26.05%

BioXcel Therapeutics Inc. currently has a PE ratio of -9.60, a price-to-book (PB) ratio of 4.28, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.31%, a ROC of -53.79% and a ROE of -69.64%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioXcel Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. BioXcel Therapeutics Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for BioXcel Therapeutics Inc. is Strong Buy (1), with a target price of $108.1, which is +213.61% compared to the current price. The earnings rating for BioXcel Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioXcel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioXcel Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.43, ATR14 : 4.60, CCI20 : -110.44, Chaikin Money Flow : -0.24, MACD : -3.00, Money Flow Index : 22.68, ROC : -13.15, RSI : 42.07, STOCH (14,3) : 6.46, STOCH RSI : 0.71, UO : 32.40, Williams %R : -93.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioXcel Therapeutics Inc. in the last 12-months were: Frank Yocca (Option Excercise at a value of $6 150), Frank Yocca (Sold 45 000 shares of value $2 318 540 ), Richard I. Steinhart (Option Excercise at a value of $20 813), Richard I. Steinhart (Sold 3 750 shares of value $180 563 ), Vincent O'Neill (Option Excercise at a value of $126 400), Vincent O'Neill (Sold 50 000 shares of value $2 626 178 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.

CEO: Vimal Mehta

Telephone: +1 475 238-6837

Address: 555 Long Wharf Drive, New Haven 06511, CT, US

Number of employees: 40

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

57%43%

Bearish Bullish

65%35%

Bearish Bullish

55%45%

News

Stocktwits